适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic MalignanciesCTIS2022-501797-19-00AvenCell Europe GmbH60
进行中（未招募）
1 期
A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapyextensive stage small cell lung cancerMedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10041067Term: Small cell lung cancer Class: 100000004864CTIS2023-509800-14-00Celgene Corp.66
尚未招募
不适用
Premarket study to assess safety and performance of the Orion Magnetic Localization System for breast cancerBreast CancerNL-OMON24152Sirius Medical Systems B.V.30
进行中（未招募）
1 期
A study to investigate VMX-C001 in healthy volunteers.To restore coagulation in patients taking DOACs who are experiencing bleeding or who require reversal of anticoagulation prior to urgent surgery.MedDRA version: 20.0Level: PTClassification code: 10009773Term: Coagulation factor X level Class: 100000004848CTIS2024-514339-87-00VarmX B.V.12
进行中（未招募）
1 期
This is clinical study to test, for the first time in people, the safety (anygood or bad effects), how long the drug can stay in the body and if it cancontrol the disease of people diagnosed with advanced cancer that has notresponded to treatment, has returned after it has been treated, or cannotbe treated by surgery, drugs, or any other known treatments.CTIS2023-509969-20-00Celgene Corp.133